Postcoital bleeding can be caused by various abnormalities of the cervix, including cervical ectropion, polyps, infection, or cervical cancer. In women presenting with postcoital bleeding, cervical cancer should be suspected if there are other symptoms such as vaginal discharge, pelvic pain, or dyspareunia. Risk factors for cervical cancer include smoking, oral contraceptive use, HPV infection, HIV infection, immunosuppression, and family history.

The primary screening tool for cervical cancer is a cervical smear, which should be done every three years for women aged 25-49. If a patient presents with postcoital bleeding, the first step is to perform a speculum examination to visualize the cervix, which can detect over 80% of cervical cancers. If the cervix appears normal, a smear may be taken if it is due, and swabs can be taken for STI testing and pregnancy testing. If symptoms persist, referral to colposcopy may be necessary.

Other tests such as blood tests, urine dipstick, and high vaginal swab may be useful in certain cases, but they are not the primary investigation for postcoital bleeding. Blood tests may be indicated later, while urine dipstick and high vaginal swab are secondary investigations following visualisation of the cervix.

In summary, speculum examination is the key initial investigation for postcoital bleeding, and cervical smear is the primary screening tool for cervical cancer. Other tests may be useful in specific situations, but they should not replace the essential role of speculum examination and cervical smear in the evaluation of postcoital bleeding.

Early latent syphilis is a stage of syphilis where the infection is present in the body but there are no visible symptoms. The recommended treatment for early latent syphilis in adults is a single dose of Benzathine penicillin G administered intramuscularly. This treatment is highly effective in curing the infection and preventing further complications. Other antibiotics such as doxycycline, amoxicillin, azithromycin, or ceftriaxone may be used as alternative treatments for patients who are allergic to penicillin. However, Benzathine penicillin G is the preferred treatment due to its high efficacy and convenience of a single dose. It is important for individuals with syphilis to seek treatment promptly to prevent the progression of the disease and reduce the risk of transmitting it to others.

The question presents a scenario of an HIV+ patient in their 60s with ongoing depression and cutaneous lesions in the form of purple-red macules on their face and neck, as well as on the mucous membranes. Given these symptoms, the most likely diagnosis would be Kaposi’s sarcoma.

Kaposi’s sarcoma is a tumor that develops due to human herpesvirus 8, and it is commonly associated with AIDS. The characteristic presentation of Kaposi’s sarcoma includes red to purple-red macules on the skin that progress to papules, nodules, and plaques. These lesions are typically found on the head, back, neck, trunk, and mucous membranes.

In this case, the presence of purple-red macules on the face, neck, and mucous membranes aligns with the typical presentation of Kaposi’s sarcoma in an HIV+ patient. Therefore, this would be the most likely diagnosis among the options provided.

Disease state vs Serology
Acute hepatitis: HBsAg, HBeAg, anti-HBc IgM
Chronic hepatitis B (low infectivity): HBsAg (>6/12), anti-HBe, anti-HBc IgG
Chronic hepatitis B (high infectivity): HBsAg (>6/12), HBeAg, anti-HBc IgG
Cleared infection: Anti-HBs, anti-HBe, anti-HBc IgG
Vaccinated: Anti-HBs

Secondary syphilis is the second stage of syphilis infection, which occurs after the initial primary stage. The signs of secondary syphilis include a generalized rash, flat wart-like genital lesions, and mouth ulcers. These symptoms typically appear 6-8 weeks after the primary ulcer, also known as a chancre, has healed. It is important to recognize these signs and seek medical attention promptly to receive appropriate treatment and prevent further complications of syphilis.

Chlamydia trachomatis is the most common cause of acute epididymo-orchitis in sexually active young adults. This patient’s symptoms and signs are consistent with epididymo-orchitis, and the timing suggests this diagnosis over testicular torsion. While mumps can also cause epididymo-orchitis, it is less common and not supported by the absence of other symptoms. In men over 35 years old, E. coli is the most common cause, but given this patient’s age and sexual history, chlamydia is the most likely culprit. Neisseria gonorrhoeae is the second most common cause in this age group.

Epididymo-orchitis is a condition where the epididymis and/or testes become infected, leading to pain and swelling. It is commonly caused by infections spreading from the genital tract or bladder, with Chlamydia trachomatis and Neisseria gonorrhoeae being the usual culprits in sexually active younger adults, while E. coli is more commonly seen in older adults with a low-risk sexual history. Symptoms include unilateral testicular pain and swelling, with urethral discharge sometimes present. Testicular torsion, which can cause ischaemia of the testicle, is an important differential diagnosis and needs to be excluded urgently, especially in younger patients with severe pain and an acute onset.

Investigations are guided by the patient’s age, with sexually transmitted infections being assessed in younger adults and a mid-stream urine (MSU) being sent for microscopy and culture in older adults with a low-risk sexual history. Management guidelines from the British Association for Sexual Health and HIV (BASHH) recommend ceftriaxone 500 mg intramuscularly as a single dose, plus doxycycline 100 mg orally twice daily for 10-14 days if the organism causing the infection is unknown. Further investigations are recommended after treatment to rule out any underlying structural abnormalities.

In the context of HIV-exposed infants, it is crucial to provide immediate protection against potential HIV transmission. By dispensing a full 6-week supply of dual prophylaxis (NVP and AZT) at birth for all HIV-exposed infants until the delivery viral load (VL) is known, healthcare providers can ensure that the infant is receiving the necessary medication to prevent HIV transmission from the mother.

This approach is recommended because it allows for early intervention and protection for the infant, especially in cases where the mother’s viral load is unknown or high. By starting the dual prophylaxis at birth, healthcare providers can minimize the risk of HIV transmission during the critical early weeks of life.

HIV-positive patients are at an increased risk for opportunistic infections (OIs) due to their compromised immune system. When a low hemoglobin level is present in these patients, it may indicate an underlying OI that is causing anemia. Anemia can be a common complication of OIs such as mycobacterium avium complex (MAC), cytomegalovirus (CMV), or disseminated histoplasmosis.

Prompt diagnosis and treatment of the underlying OI is crucial in these cases to prevent further complications and improve the patient’s overall health.

In contrast, conditions such as hyperlipidemia, immune reconstitution inflammatory syndrome (IRIS), osteoporosis, and lipomastia may also be present in HIV-positive patients, but they do not typically present with a low hemoglobin level as a primary symptom. Therefore, when a low hemoglobin level is identified in an HIV-positive patient, the focus should be on ruling out and treating any underlying opportunistic infections.

Initiating antiretroviral therapy (ART) for newly diagnosed or known HIV-positive women not on ART the following day after excluding contra-indications is important for preventing mother-to-child transmission of HIV. By starting ART promptly, the viral load in the mother’s body can be suppressed, reducing the risk of transmission to the baby during labor and delivery. This timing allows for the maximum benefit of ART to be achieved in terms of reducing the risk of transmission.

Delaying the initiation of ART until after the first postnatal visit or only if the mother requests it may increase the risk of transmission to the baby. Therefore, it is recommended to start ART as soon as possible after diagnosis, once any contraindications have been ruled out. This approach is in line with current guidelines for the prevention of mother-to-child transmission of HIV and can significantly improve the health outcomes for both the mother and the baby.

Steps to manage a patient in primary care:

• Confirm the Diagnosis:
  • HIV Testing: Ensure that the HIV diagnosis is confirmed through appropriate testing, typically with two different types of HIV tests to avoid false positives.
• Baseline Assessment:
  • Medical History and Physical Examination: Obtain a detailed medical history, including any symptoms, previous illnesses, and risk factors. Conduct a thorough physical examination.
  • Baseline Laboratory Tests: These should include:
    • CD4 Count: To assess the patient’s immune status.
    • Viral Load: To determine the level of HIV in the blood.
    • Complete Blood Count (CBC): To check for anemia, leukopenia, or thrombocytopenia.
    • Liver and Kidney Function Tests: To evaluate the patient’s overall health and potential contraindications for certain medications.
    • Screening for Opportunistic Infections: Tests for tuberculosis, hepatitis B and C, and sexually transmitted infections (STIs).
• Counseling and Education:
  • HIV Education: Provide the patient with information about HIV, its transmission, and the importance of adherence to antiretroviral therapy (ART).
  • Treatment Expectations: Discuss the benefits and potential side effects of ART.
  • Adherence Counseling: Emphasize the importance of taking ART consistently and the impact of adherence on treatment success.
  • Disclosure and Support: Offer counseling on the importance of disclosing their HIV status to sexual partners and provide support options.

Once these steps have been taken, one can start initiating treatment.

• Initiate Antiretroviral Therapy (ART):
  • Selection of ART Regimen: Follow the national guidelines (NDOH 2020 guidelines for treatment initiation), typically involving a combination of three antiretroviral drugs.
  • First-Line Regimen: Common first-line regimens in South Africa may include a combination of Tenofovir (TDF), Lamivudine (3TC), and Dolutegravir (DTG).

Hepatitis E is the correct answer for this question because it is known to have a much higher mortality rate in pregnant females compared to non-pregnant females. This is especially true in third world countries where access to proper medical care and sanitation may be limited. Hepatitis E is transmitted through contaminated water or food, making pregnant women more susceptible to the virus due to their weakened immune systems. In contrast, Hepatitis A, B, and C do not typically have as high of a mortality rate in pregnant women. Hepatitis E is a serious concern for pregnant women in developing countries and highlights the importance of access to clean water and proper healthcare during pregnancy.

HIV-associated nephropathy (HIVAN) is a common complication of HIV infection, particularly in individuals of African descent. It is characterized by renal dysfunction, proteinuria, and progressive renal failure.

A renal biopsy in a patient with HIVAN would typically show microcystic tubular dilatation and collapsing FSGS (focal segmental glomerulosclerosis). FSGS is a pattern of scarring in the kidney that can lead to proteinuria and eventually kidney failure. The collapsing variant of FSGS is particularly associated with HIVAN and is characterized by prominent podocytes and collapsing capillary loops.

Other possible findings on renal biopsy in HIVAN may include Kimmelstiel-Wilson lesions, which are characteristic of diabetic nephropathy, but can also be seen in HIVAN. Minimal-change disease, focal necrotizing crescentic nephritis, and membranous nephropathy are less likely to be seen in HIVAN.

In this case, the patient’s clinical presentation of swollen ankles, elevated plasma creatinine, significant proteinuria, and echogenic kidneys on ultrasound are all consistent with a diagnosis of HIVAN. A renal biopsy showing microcystic tubular dilatation and collapsing FSGS would confirm the diagnosis.

Adherence to antiretroviral therapy (ART) is crucial for the successful management of HIV/AIDS. Encouraging clients to discontinue ART during periods of travel is not recommended as it can lead to treatment interruptions and decreased viral suppression. This can result in the development of drug resistance and compromised immune function.

On the other hand, interventions such as mobile phone reminders, home-based care, community-based adherence clubs, and peer support groups have been shown to be effective in supporting adherence to ART and retention in care. Mobile phone reminders can help clients remember to take their medication on time, while home-based care can provide support and monitoring in a familiar environment. Community-based adherence clubs and peer support groups offer social support and a sense of belonging, which can motivate clients to stay on track with their treatment.

In this case, the patient presented with a productive cough with rusty coloured sputum, which is a common symptom of pneumonia. The chest X-ray showed lobar consolidation on the left side, indicating a specific type of pneumonia known as lobar pneumonia.

Streptococcus pneumoniae is the most likely causative organism in this scenario. This bacterium is a common cause of community-acquired pneumonia, especially in adults. It is known to cause lobar pneumonia, which is characterized by consolidation of an entire lobe of the lung.

Haemophilus influenzae is another common cause of pneumonia, but it is more commonly associated with bronchitis and exacerbations of chronic obstructive pulmonary disease (COPD). Legionella pneumophila is known to cause Legionnaires’ disease, which presents with symptoms similar to pneumonia but is usually associated with contaminated water sources.

Mycobacterium tuberculosis is the causative organism for tuberculosis, which typically presents with a chronic cough, weight loss, and night sweats. Pneumocystis jiroveci is a fungus that causes pneumonia in immunocompromised individuals, such as those with HIV/AIDS.

Overall, based on the patient’s presentation and the chest X-ray findings, Streptococcus pneumoniae is the most likely causative organism for the lobar pneumonia in this 43-year-old female patient.

Squamous cell carcinoma of the cervix is often caused by the human papillomavirus (HPV), particularly strains 16 and 18. HPV infects the host and interferes with genes that regulate cell growth, leading to uncontrolled growth and inhibition of apoptosis. This results in precancerous lesions that can progress to carcinoma. Risk factors for cervical carcinoma include smoking, low socioeconomic status, use of the contraceptive pill, early sexual activity, co-infection with HIV, and a family history of cervical carcinoma. HIV is not the cause of cervical squamous cell carcinoma, but co-infection with HIV increases the risk of HPV infection. Epstein-Barr virus (EBV) is associated with other types of cancer, but not cervical squamous cell carcinoma. Chlamydia trachomatis is a bacterium associated with genitourinary infections, while herpes simplex virus (HSV) causes painful ulceration of the genital tract but is not associated with cervical carcinoma.

Hepatitis C Management and Testing

Hepatitis C is a viral infection that can be acquired through blood or sexual contact, including shared needles during intravenous drug use and contaminated blood products. While some patients may be asymptomatic, the virus can cause progressive damage to the liver and may lead to liver failure requiring transplantation if left untreated.

Before starting treatment for chronic hepatitis C, it is important to determine the patient’s hepatitis C genotype, as this guides the length and type of treatment and predicts the likelihood of response. Dual therapy with interferon α and ribavirin is traditionally the most effective treatment, but newer oral medications like sofosbuvir, boceprevir, and telaprevir are now used in combination with PEG-interferon and ribavirin for genotype 1 hepatitis C.

Screening for HIV is also important, as HIV infection often coexists with hepatitis C, but the result does not influence hepatitis C management. An ultrasound of the abdomen can determine the structure of the liver and the presence of cirrhosis, but it does not alter hepatitis C management. A chest X-ray is not necessary in this patient, and ongoing intravenous drug use does not affect hepatitis C management.

Overall, proper testing and management of hepatitis C can prevent further liver damage and improve patient outcomes.

Pregnant healthcare workers who experience a high-risk needle stick in the first trimester are recommended to be put on the TLD regimen for PEP. This regimen consists of tenofovir (TDF), lamivudine (3TC), and dolutegravir (DTG). This recommendation is based on the National Department of Health (NDOH), which suggests that this combination is safe and effective for pregnant women in their first trimester.

The first viral load (VL) measurement after initiating antiretroviral therapy (ART) is crucial in monitoring the effectiveness of the treatment in suppressing the HIV virus. By taking the VL after 3 dispensing cycles, healthcare providers can assess how well the medication is working and whether the patient is responding positively to the treatment. This early check allows for any necessary adjustments to be made to the treatment plan if the viral load is not decreasing as expected. Additionally, monitoring the VL early on can help identify any potential issues or challenges that may arise in achieving viral suppression. Therefore, it is important to follow the guidelines and take the first VL measurement after 3 dispensing cycles to ensure the best possible outcomes for the patient.

Isoniazid (INH) is a medication commonly used for the treatment and prevention of tuberculosis (TB). When it comes to TB-exposed neonates, it is important to provide them with the appropriate duration of INH dosing to ensure effective treatment and prevention of the disease.

The maximum duration of isoniazid (INH) dosing for TB-exposed neonates is typically recommended to be 6 months. This duration is based on clinical guidelines and studies that have shown that a 6-month course of INH is effective in preventing the development of active TB in neonates who have been exposed to the disease.

While longer durations of INH dosing may be considered in certain cases, such as if the neonate is at high risk for developing TB or if there are other complicating factors, the standard recommendation is to provide a 6-month course of treatment. This duration strikes a balance between providing adequate protection against TB and minimizing the potential for side effects or complications associated with prolonged medication use.

Overall, the 6-month duration of isoniazid (INH) dosing for TB-exposed neonates is based on evidence-based guidelines and recommendations to ensure the best possible outcomes for these vulnerable patients.

Prevalence in epidemiology refers to the proportion of a population that has a specific condition at a given point in time. This can be expressed as a fraction, percentage, or number of cases per 10,000 or 100,000 people. Point prevalence specifically looks at the proportion of the population with the condition at a specific point in time, while period prevalence considers the proportion of the population that has the condition at some point during a given period.

Lifetime prevalence, on the other hand, looks at the proportion of the population that has experienced the condition at some point in their life up to the time of assessment. This includes individuals who may have had the condition in the past but no longer have it.

In the context of infectious diseases, prevalence can help public health officials understand the burden of a disease within a population and inform strategies for prevention and control. Sero-prevalence and seroconversion specifically refer to the prevalence of antibodies in a population and the rate at which individuals develop antibodies, respectively.

Overall, prevalence is an important measure in epidemiology that provides valuable information about the distribution of diseases and risk factors within a population.

During pregnancy, the risk of maternal-fetal transmission of Toxoplasma Gondii is highest during the later stages, specifically between 26-40 weeks. This is because as the pregnancy progresses, the placenta becomes more permeable and allows for easier transmission of the parasite from the mother to the fetus. Additionally, the immune system of the fetus is not fully developed until later in pregnancy, making it more susceptible to infection.

On the other hand, the risk of transmission is lower in early pregnancy, particularly before 10 weeks, because the placenta is not fully formed and the immune system of the fetus is not yet developed. However, if infection does occur earlier in pregnancy, the complications are typically more severe as the parasite can affect the development of the fetus.

Overall, it is important for pregnant women to take precautions to prevent Toxoplasma Gondii infection throughout their pregnancy, but especially during the later stages when the risk of transmission is highest. This can include avoiding raw or undercooked meat, washing fruits and vegetables thoroughly, and avoiding contact with cat feces. Regular prenatal check-ups and screenings can also help detect and manage any potential infections.

Among people living with HIV in 2021, approximately 85% knew their HIV status according to WHO estimates.

efavirenz is known to cause central nervous system side effects, including dizziness and ataxia, in some patients. These side effects typically occur within the first few weeks of starting the medication and may improve over time as the body adjusts to the drug. It is important for healthcare providers to monitor patients closely for these side effects and to consider alternative medications if they persist or worsen.

Cryptococcal meningitis is a serious fungal infection that affects the brain and spinal cord, particularly in individuals with weakened immune systems such as those living with HIV. The recommended treatment for cryptococcal meningitis in this population is combination therapy with amphotericin B and fluconazole.

Amphotericin B is a potent antifungal medication that is effective in treating cryptococcal meningitis. It is typically administered intravenously to achieve high levels in the cerebrospinal fluid where the infection is located. However, amphotericin B can have significant side effects, including kidney toxicity, which is why it is often used in combination with another antifungal medication.

Fluconazole is an oral antifungal medication that is also effective in treating cryptococcal meningitis. When used in combination with amphotericin B, fluconazole helps to enhance the effectiveness of the treatment and reduce the risk of relapse. This combination therapy has been shown to improve outcomes and reduce mortality rates in patients with cryptococcal meningitis.

Overall, combination therapy with amphotericin B and fluconazole is the recommended treatment for cryptococcal meningitis in adults, adolescents, and children living with HIV who test positive for cryptococcal antigen (CrAg) in cerebrospinal fluid (CSF). It is important for healthcare providers to closely monitor patients receiving this treatment to ensure optimal outcomes and manage any potential side effects.

Congenital cytomegalovirus (CMV) infection is a common viral infection that can be passed from a mother to her baby during pregnancy. Infants born with congenital CMV infection may present with a variety of symptoms, including jaundice, hepatosplenomegaly (enlargement of the liver and spleen), petechiae (small red or purple spots on the skin), microcephaly (abnormally small head size), hearing loss, and seizures.

In this case, the 3-month-old infant born to an HIV positive mother presented with jaundice, epileptic seizures, and microcephaly. Given these symptoms, the most likely cause would be congenital cytomegalovirus infection. Other viral infections such as Epstein-Barr virus, measles, rubella, and varicella can also cause similar symptoms, but the combination of jaundice, seizures, and microcephaly is most commonly associated with CMV infection.

It is important to diagnose and manage congenital CMV infection early to prevent long-term complications such as hearing loss and developmental delays. Testing for CMV infection can be done through blood tests, urine tests, or saliva tests. Treatment may include antiviral medications and supportive care to manage symptoms.

Among the given options, the most likely cause for the patient’s presenting symptoms is acute interstitial nephritis secondary to anti-tubercular therapy (ATT)
Drug-induced acute interstitial nephritis can occur following treatment with beta-lactams, sulphonamides, rifampicin, ethambutol, and erythromycin. They can cause an acute allergic reaction with the infiltration of immune cells.
Acute interstitial nephritis is said to be the most common renal complication in patients undergoing anti-TB treatment. Rifampicin is the most implicated drug, although ethambutol can also be a cause. The pathogenesis involves an immune-complex mediated acute allergic response, which leads to their deposition on renal vessels, the glomerular endothelium, and the interstitial area.

Other options:
Isoniazid does not affect the kidneys.
Pulmonary-renal syndrome is a feature of Goodpasture’s syndrome. It is characterized by renal failure and lung haemorrhage. Severe cardiac or renal failure ensues and is complicated by pulmonary oedema, systemic lupus erythematosus, Henoch-Schönlein purpura, and cryoglobulinemia.

The conditions that need to be notified to the consultant responsible for communicable disease control are typically those that are highly contagious and have the potential to spread rapidly within a community. Pneumococcal pneumonia, Pneumococcal meningitis, Campylobacter food poisoning, E. coli H0157 food poisoning, and Vivax malaria are all conditions that fall into this category.

However, Vivax malaria does not belong to the list of diseases that need to be notified to relevant authorities to prevent or reduce their spread. While malaria is a serious and potentially life-threatening disease, it is not considered highly contagious in the same way as the other conditions listed. Malaria is primarily spread through the bite of an infected mosquito and does not typically spread directly from person to person.

Therefore, Vivax malaria is the condition that does not belong to the category of diseases that need to be notified to the consultant responsible for communicable disease control.

Repeat viral load testing is an important aspect of monitoring HIV treatment effectiveness in clients. The range of viral load considered for clients with repeat testing helps healthcare providers determine the level of viral replication in the body and assess the response to antiretroviral therapy.

A viral load of < 10 c/mL is considered undetectable and indicates successful suppression of the virus. This is the ideal outcome for clients on HIV treatment. A viral load of 10-49 c/mL is still considered low and may not necessarily indicate treatment failure, but it does warrant closer monitoring. A viral load of 50-999 c/mL falls within the range of persistent low-grade viremia. This level of viral replication may indicate suboptimal adherence to treatment or the development of drug resistance. Clients in this range require careful monitoring and potential interventions to address any issues that may be affecting treatment efficacy. A viral load of ≥ 1000 c/mL is considered high and indicates treatment failure. This level of viral replication may lead to disease progression and the development of complications. Clients with a viral load in this range may need to switch to a different antiretroviral regimen to achieve viral suppression. Therefore, the correct answer to the question is 50-999 c/mL, as clients falling within this range on repeat viral load testing are categorized as having persistent low-grade viremia and require closer monitoring and potential interventions to optimize treatment adherence and efficacy.

PrEP, or pre-exposure prophylaxis, is a medication taken by individuals who are at high risk of contracting HIV to prevent infection. On-demand dosing refers to taking PrEP only around the time of potential exposure to HIV, rather than taking it daily.

The drug of choice for on-demand dosing specifically for MSM (men who have sex with men) and transgender women is TDF/FTC (tenofovir disoproxil fumarate/emtricitabine) taken 2-24 hours before sex. This combination of drugs has been shown to be highly effective in preventing HIV transmission when taken in this manner.

The HIVCS 2020 update recommends a 2:1:1 strategy with TDF/FTC for MSM and transgender women, meaning that individuals should take two pills 2-24 hours before sex, and then continue with one pill daily for the next two days. This strategy has been found to be effective in reducing the risk of HIV transmission in these populations.

It is important for individuals considering on-demand PrEP dosing to consult with a healthcare provider to determine the best regimen for their specific needs and circumstances.

ART initiation is deferred by four weeks in clients with confirmed cryptococcal meningitis on lumbar puncture to optimize the effectiveness of antifungal treatment.